Combining SARS-CoV-2 Proofreading Exonuclease and RNA-Dependent RNA Polymerase Inhibitors as a Strategy to Combat COVID-19: A High-Throughput in silico Screening

Combining SARS-CoV-2 Proofreading Exonuclease and RNA-Dependent RNA Polymerase Inhibitors as a Strategy to Combat COVID-19: A High-Throughput in silico Screening

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions of people worldwide. Currently, many clinical trials in search of effective COVID-19 drugs are underway. Viral RNA-dependent RNA polymerase (RdRp) remains the target of choice for prophylactic or curative treatment of...

Full description

Bibliographic Details
Main Authors: Shradha Khater, Pawan Kumar, Nandini Dasgupta, Gautam Das, Shashikant Ray, Amresh Prakash
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Microbiology
Subjects:
SARS-CoV-2
drug repurposing
exonuclease inhibitor
nucleoside analog
molecular docking and MD simulation
combinatorial therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fmicb.2021.647693/full

Internet

https://www.frontiersin.org/articles/10.3389/fmicb.2021.647693/full

Similar Items